Document Detail


Progress report on the potential of angiogenesis inhibitors for neuro-oncology.
MedLine Citation:
PMID:  15565816     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
New therapies for brain tumors are urgently needed. Brain tumors are highly vascularized, supporting the potential of anti-angiogenic therapies in their treatment. The promise of blocking tumor growth through inhibiting new blood vessel formation with anti-angiogenic agents has been heralded as a therapeutic breakthrough, and pre-clinical data supported this enthusiasm. However, early clinical trials in humans have been somewhat disappointing. Nonetheless, great optimism for these agents remains, and many new anti-angiogenic agents and strategies are being evaluated pre-clinically and in clinical trials. A number of issues need to be considered in the application of these agents to neuro-oncology. In this review, we discuss the biology of blood vessel formation in the brain and brain tumors as it relates to anti-angiogenic therapies. The difficulties inherent in performing clinical trials of anti-angiogenic therapies in patients with brain tumors are outlined. Finally, we consider numerous individual antiangiogenic and antivascular therapies now in pre-clinical testing or in clinical trials.
Authors:
Benjamin Purow; Howard A Fine
Related Documents :
25378856 - Pulmonary tumor thrombotic microangiopathy in an unknown primary cancer.
213226 - Role of tissue culture in prediction of malignancy.
14644076 - Adamts-13 activity in patients with brain and prostate tumors is mildly reduced, but no...
9868806 - In vitro and in vivo porphyrin accumulation by c6 glioma cells after exposure to 5-amin...
12173046 - Mismatch repair deficiency in hematological malignancies with microsatellite instability.
16952846 - New target-based agents involve new clinical trial designs.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Cancer investigation     Volume:  22     ISSN:  0735-7907     ISO Abbreviation:  Cancer Invest.     Publication Date:  2004  
Date Detail:
Created Date:  2004-11-29     Completed Date:  2004-12-07     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8307154     Medline TA:  Cancer Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  577-87     Citation Subset:  IM    
Affiliation:
Neuro-Oncology Branch, National Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-4089, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / therapeutic use*
Antineoplastic Agents / therapeutic use
Brain Neoplasms / blood supply,  drug therapy*
Clinical Trials as Topic
Humans
Neovascularization, Pathologic
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antineoplastic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials...
Next Document:  The tuberous sclerosis complex genes in tumor development.